Advances in Systemic Therapy for Ovarian Cancer Over the Past Decade: A Clinical and Molecular Perspective

Monika Abramiuk; Ilona Skrabalak; Malgorzata Satora; Marta Ostrowska-Leśko; Maja Joanna Czech; Julia Majchrzak; Marcin Bobiński

doi:10.12659/MSM.949526

28 August 2025 : Review article

Advances in Systemic Therapy for Ovarian Cancer Over the Past Decade: A Clinical and Molecular Perspective

Monika Abramiuk

^{AEFG 1*}, Ilona Skrabalak

^{EF 2}, Malgorzata Satora

^{AEF 3}, Marta Ostrowska-Leśko

^{AEFG 2}, Maja Joanna Czech^{EF 4}, Julia Majchrzak^{EF 4}, Marcin Bobiński

^{AFG 2}

DOI: 10.12659/MSM.949526

Med Sci Monit 2025; 31:e949526

Authors information Article notes Copyright and License information

Introduction Characteristics of Ovarian Cancer The Idea of Tailored Therapy Mechanisms of Action of Currently Used Agents Clinical Utilization of Targeted Treatments Upcoming Advances Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 4 Clinical trials concerning WEE1 inhibitors in ovarian cancer.

Intervention (drug)	Conditions	Phase	Status	ClinicalTrials.gov ID	Publications
Adavosertib + durvalumab	Advanced solid tumours	I	Active, not recruiting	NCT02617277 []¹⁴¹	[]¹²⁴
Debio 0123 + carboplatin	Advanced solid tumors	I	Recruiting	NCT03968653	–
Adavosertib	Advanced high-grade ovarian, fallopian tube, or primary peritoneal cancer	I	Active, not recruiting	NCT02659241 []¹⁴²	[]¹²⁵
Adavosertib + olaparib	Advanced solid tumors with selected mutations and parp resistance, star study	I	Active, not recruiting	NCT04197713	–
Adavosertib	Locally advanced or metastatic solid tumors	Ib	Completed	NCT02610075 []¹⁴³	[]¹²⁶
Adavosertib	Advanced solid tumors	Ib	Completed	NCT02482311 []¹⁴⁴	[]¹²⁷
Adavosertib + carboplatin	TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months	II	Completed	NCT01164995 []¹⁴⁵	[]¹²⁸
Adavosertib;Adavosertib + olaparib	Recurrent ovarian, fallopian tube or primary peritoneal cancer with documented progressive disease on a PARPi were eligible	II	Recruiting	NCT03579316 []¹⁴⁶	[]¹²⁹
Adavosertib + paclitaxel + carboplatin	TP53-mutated, platinum-sensitive ovarian cancer	II	Completed	NCT01357161 []¹⁴⁷	[]¹³⁰
Adavosertib + gemcitabine;Adavosertib + paclitaxel;Adavosertib + carboplatin;Adavosertib + pegylated liposomal doxorubicin	Platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer	II	Completed	NCT02272790 []⁹⁹	[]¹⁴⁸
Adavosertib + gemcitabine hydrochloride	Recurrent ovarian, primary peritoneal, or fallopian tube cancer	II	Active, not recruiting	NCT02101775 []¹⁴⁹	[]¹³¹
ZN-c3 + Chemotherapy	Platinum-resistant or -refractory ovarian cancer	I	Recruiting	NCT04516447	–

Back to the Article

Advances in Systemic Therapy for Ovarian Cancer Over the Past Decade: A Clinical and Molecular Perspective

Your Privacy